REFERENCES
  1. Thouvenot É. Update on clinically isolated syndrome. Presse Med(2015) 44(4 Pt 2):e121-36. doi: 10.1016/j.lpm.2015.03.002.
  2. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes.Lancet Neurol (2012) 11(2):157-69. doi: 10.1016/S1474-4422(11)70274-5.
  3. Petržalka M, Meluzínová E, Libertínová J, Mojžišová H, Hanzalová J, Ročková P. IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis. PLoS One (2022) 17(6):e0270607. doi: 10.1371/journal.pone.0270607.
  4. Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK. The Cerebrospinal Fluid in Multiple Sclerosis. Front Immunol (2019) 10:726. doi: 10.3389/fimmu.2019.00726.
  5. Arneth BM. Impact of B cells to the pathophysiology of multiple sclerosis. J Neuroinflammation (2019) 16(1):128. doi: 10.1186/s12974-019-1517-1.
  6. Bhargava P, Hartung HP, Calabresi PA. Contribution of B cells to cortical damage in multiple sclerosis. Brain (2022) 145(10):3363-3373. doi: 10.1093/brain/awac233.
  7. Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler (2013) 19(9):1204-8. doi: 10.1177/1352458512473362.
  8. Hartung HP, Aktas O, Menge T, Kieseier CK. Immune regulation of multiple sclerosis. Handb Clin Neurol (2014) 122:3-14. doi: 10.1016/B978-0-444-52001-2.00001-7.
  9. Bielekova B, Komori M, Xu Q, Reich DS, Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. Plos One (2012) 7(11):e48370. doi: 10.1371/journal.pone.0048370.
  10. Matejčíková Z, Mareš J, Přikrylová Vranová H, Klosová J, Sládková V, Doláková J, et al. Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study (2015). J Neural Transm (Vienna) 122(2):273-7. doi: 10.1007/s00702-014-1244-9.
  11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
  12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ”McDonald Criteria”. Ann Neurol (2005) 58(6):840-6. doi: 10.1002/ana.20703.
  13. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett (1992) 307(1):97-101.  doi: 10.1016/0014-5793(92)80909-z.
  14. Legle DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolono M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5.J Exp Med (1998) 187(4):655-60. doi: 10.1084/jem.187.4.655.
  15. Wagner JN, Weis S, Kubasta C, Panholzer J, von Oertzen T.J. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients. J Neurol (2018) 265, 74-81. doi: 10.1007/s00415-017-8669-7.
  16. Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, et al. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute lyme neuroboreliosis. J neuroinflammation (2009) 6, 42. doi: 10.1186/1742-2094-6-42.
  17. Sapko K, Jamroz-Wiśniewska A, Marciniec M, Kulczyński M, Szczepańska-Szerej A, Rejdak K. Biomarkers in Multiple Sclerosis: a review of diagnostic and prognostic factors. Neurol Neurochir Pol (2020) 54(3):252-258. doi: 10.5603/PJNNS.a2020.0037.
  18. Bartosik-Psujek H, Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol (2005) 12(1):49-54. doi: 10.1111/j.1468-1331.2004.00951.x.
  19. Stelmasiak Z, Kozioł-Montewka M, Dobosz B, Rejdak K, Bartosik-Psujek H, Mitosek-Szewczyk K, et al. Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit (2000) 6(6):1104-8.
  20. Matejčíková Z, Mareš J, Sládková V, Svrčinová T, Vysloužilová J, Zapletalová J, et al. Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. Mult cler Relat Disord (2017) 14:12-15. doi: 10.1016/j.msard.2017.03.007.
  21. Rossi S, Motta C, Studer V, Macchiarulo G, Germani G, Finardi A, et al. Subclinical central inflammation is risk for RIS and CIS conversion to MS. Mult Scler (2015) 21(11):1443-52.
  22. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg, F, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler(2011) 17(3):335-43. doi: 10.1177/1352458510389102.
  23. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One (2010) 5, e11986. doi: 10.1371/journal.pone.0011986.
  24. Lepennetier G, Hracsko Z, Unger M, Van Griesven M, Grummel V, Krumbholz M, et al. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases.J Neuroinflammation (2019) 16(1):219.  doi: 10.1186/s12974-019-1601-6.
  25. Ferraro D, Galli V, Vitetta F, Simone AM, Bedin R, Del Giovane C, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis. J Neuroimmunol (2015) 283:64-9. doi: 10.1016/j.jneuroim.2015.04.011.
  26. DiSano KD, Gilli F, Pachner AR. Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis. Mult Scler J Exp Tranl Clin (2020) 6(4). doi: 10.1177/2055217320981396.